Cancel
Trial Spark
Trial Spark Employees
5 people indexed:
-
j4v@wffzgh272j.h5d Sign up to see email
-
9045@0qu58v3dq3.f2g Sign up to see email
-
z26ny@9d47nq748h.2xu Sign up to see email
-
qdgj6x@7wz55z01y6.3x8 Sign up to see email
-
w9qdx16@81v2bz5qb2.fj5 Sign up to see email
Trial Spark Company Information
Trial Spark is a company with a mission to expedite the delivery of new treatments to patients by acquiring clinical-stage drugs from pharmaceutical companies, universities, and biotech firms and developing them more efficiently through its proprietary technology-driven platform. The company emphasizes radical efficiency throughout the drug development lifecycle while maintaining high standards of quality and safety. Trial Spark’s team and advisors, who have experience with over 45 approved drugs, bring expertise in drug selection, development, and technology integration. The company has attracted investment from notable technology and biosciences investors such as Sam Altman, Michael Moritz, Sequoia Capital, Thrive Capital, Section 32, and John Doerr. Its current pipeline includes ASN008, which is in Phase 2 for treating itch associated with Atopic Dermatitis; Gusacitinib, in Phase 3 for Chronic Hand Eczema; and Sprifermin, also in Phase 2 for Knee Osteoarthritis.
Report inaccurate information
Report inaccurate information